{"filing":{"accession_number":"0001628280-26-053824","cik":"0001228627","ticker":"IRD","company_name":"Opus Genetics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ird-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-20260806.htm"},"events":[{"id":25857,"run_id":23474,"accession_number":"0001628280-26-053824","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenue of $0.8 million, R\u0026D expenses of $11.2 million, G\u0026A expenses of $6.0 million, and a net loss of $8.1 million ($0.08 per basic share). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements and a corporate pipeline update. This is material to investors as it provides quarterly financial performance and clinical development milestones for a clinical-stage biopharmaceutical company.","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26789,"accession_number":"0001628280-26-053824","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenue of $0.8 million, R\u0026D expenses of $11.2 million, G\u0026A expenses of $6.0 million, and a net loss of $8.1 million ($0.08 per basic share). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements and a corporate pipeline update. This is material to investors as it provides quarterly financial performance and clinical development milestones for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:03.157389+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26789,"accession_number":"0001628280-26-053824","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenue of $0.8 million, R\u0026D expenses of $11.2 million, G\u0026A expenses of $6.0 million, and a net loss of $8.1 million ($0.08 per basic share). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements and a corporate pipeline update. This is material to investors as it provides quarterly financial performance and clinical development milestones for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:03.157389+00:00","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-08-06"}]}